SYK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Stryker Corp (SYK) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite strong financial performance and positive analyst sentiment, technical indicators and trading trends do not suggest an optimal entry point. The stock's pre-market movement is minimal, and hedge funds are selling. It is better to hold off on buying until stronger positive signals emerge.
The stock's MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 34.143, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 339.497, with key support at 327.724 and resistance at 351.27. Overall, technical indicators suggest a bearish trend.
Stryker has restored most of its manufacturing operations after a cyberattack, which could stabilize operations. The company reported strong Q4 financials with double-digit revenue and net income growth. Analysts highlight robust fundamentals in the medical technology sector.
Hedge funds are selling, with a 119.77% increase in selling activity last quarter. Technical indicators are bearish, and the stock shows a higher probability of declining in the next week and month. No recent congress trading data or significant insider activity to support bullish sentiment.
In Q4 2025, Stryker reported revenue growth of 11.42% YoY to $7.17 billion and net income growth of 55.49% YoY to $849 million. EPS increased by 56.03% to 2.2. However, gross margin slightly declined to 62.61%, down 0.46% YoY.
Analysts have mixed views. UBS recently lowered its price target to $380, maintaining a Neutral rating. However, Citi and other firms maintain Buy ratings with price targets ranging from $412 to $469. Analysts highlight strong fundamentals and growth potential, but some express concerns about valuation.
